Potential cardiovascular effects of incretin-based therapies

References

• Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in Type II diabetic patients and in healthy subjects. Diabetes44, 1126–1131 (1995).
   PubMed Web of Science ®Google Scholar
• Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for Type 2 diabetes. Diabetes47, 1663–1670 (1998).
   PubMed Web of Science ®Google Scholar
• Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med.339, 229–234 (1998).
   PubMed Web of Science ®Google Scholar
• Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett.358, 219–224 (1995).
   PubMed Web of Science ®Google Scholar
• Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology137, 2968–2978 (1996).
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology132, 2131–2157 (2007).
   PubMed Web of Science ®Google Scholar
• Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation117, 2340–2350 (2008).
   PubMed Web of Science ®Google Scholar
• Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia–reperfusion injury. Diabetes54, 146–151 (2005).
   PubMed Web of Science ®Google Scholar
• Bose AK, Mocanu MM, Carr RD, Yellon DM. Myocardial ischaemia–reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc. Drugs Ther.21, 253–256 (2007).
   PubMed Web of Science ®Google Scholar
• Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia–reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res.61, 448–460 (2004).
   PubMed Web of Science ®Google Scholar
• Nyström T, Gutniak MK, Zhang Q et al. Effects of glucagon-like peptide-1 on endothelial function in Type 2 diabetes patients with stable coronary artery disease. Am. J. Physiol. Endocrinol. Metab.287, e1209–e1215 (2004).
   PubMed Web of Science ®Google Scholar
• Usdin TB, Mezey E, Button DC, Brownstein MJ, Bonner TI. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology133, 2861–2870 (1993).
   PubMed Web of Science ®Google Scholar
• Zhong Q, Bollag RJ, Dransfield DT et al. Glucose-dependent insulinotropic peptide signaling pathways in endothelial cells. Peptides21, 1427–1432 (2000).
   PubMedGoogle Scholar
• Bose AK, Mocanu MM, Carr RD, Yellon DM. Glucagon like peptide-1 is protective against myocardial ischemia–reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc. Drugs Ther.19, 9–11 (2005).
   PubMed Web of Science ®Google Scholar
• Sonne DP, Engstrøm T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia-reperfusion injury in rat heart. Regul. Pept.146, 243–249 (2008).
   PubMed Web of Science ®Google Scholar
• Noyan-Ashraf MH, Momen MA, Ban K et al. The GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes following experimental myocardial infarction in mice. Diabetes58, 975–983 (2009).
   PubMed Web of Science ®Google Scholar
• Bao W, Aravindhan K, Alsaid H et al. Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia–reperfusion injury: evidence for improving cardiac metabolic efficiency. PLoS One6, e23570 (2010).
   Google Scholar
• Sauvé M, Ban K, Momen MA et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes59, 1063–1073 (2010).
   PubMed Web of Science ®Google Scholar
• Hausenloy DJ, Wynne AM, Theodorou L, Mocanu MM, Yellon DM. Dipeptidyl peptidase IV inhibitors limit myocardial infarct size in a glucose-sensitive manner. Heart96, e11 (2010) (Abstract FC1).
   Google Scholar
• Zhao T, Parikh P, Bhashyam S et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J. Pharmacol. Exp. Ther.317, 1106–1113 (2006).
   PubMed Web of Science ®Google Scholar
• Ravassa S, Zudaire A, Carr RD, Díez J. Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol.300, H1361–H1372 (2011).
   PubMed Web of Science ®Google Scholar
• Lenski M, Kazakov A, Marx N, Böhm M, Laufs U. Effects of DPP-4 inhibition on cardiac metabolism and function in mice. J. Mol. Cell Cardiol.51, 906–918 (2011).
   PubMed Web of Science ®Google Scholar
• Belke DD, Larsen TS, Gibbs EM, Severson DL. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am. J. Physiol. Endocrinol. Metab.279, E1104–E1113 (2000).
   PubMed Web of Science ®Google Scholar
• Dokken BB, La Bonte LR, Davis-Gorman G, Teachey MK, Seaver N, McDonagh PF. Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Horm. Metab. Res.43, 300–305 (2011).
   PubMed Web of Science ®Google Scholar
• Ban K, Kim KH, Cho CK et al. Glucagon-like peptide (GLP)-1(9–36) amide-mediated cytoprotection is blocked by exendin(9–39) yet does not require the known GLP-1 receptor. Endocrinology151, 1520–1531 (2010).
   PubMed Web of Science ®Google Scholar
• Nikolaidis LA, Doverspike A, Hentosz T et al. Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J. Pharmacol. Exp. Ther.312, 303–308 (2005).
   PubMed Web of Science ®Google Scholar
• Kavianipour M, Ehlers MR, Malmberg K et al. Glucagon-like peptide-1 (7–36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides24, 569–578 (2003).
   PubMed Web of Science ®Google Scholar
• Kristensen J, Mortensen UM, Schmidt M, Nielsen PH, Nielsen TT, Maeng M. Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model. BMC Cardiovasc. Disord.9, 31 (2009).
   PubMed Web of Science ®Google Scholar
• Timmers L, Henriques JP, de Kleijn DP et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J. Am. Coll. Cardiol.53, 501–510 (2009).
   PubMed Web of Science ®Google Scholar
• Nikolaidis LA, Mankad S, Sokos GG et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation109, 962–965 (2004).
   PubMed Web of Science ®Google Scholar
• Read PA, Khan FZ, Dutka DP. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart doi:10.1136/hrt.2010.219345 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ. Cardiovasc. Imaging3, 195–201 (2010).
   PubMed Web of Science ®Google Scholar
• Read PA, Hoole SP, White PA et al. A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ. Cardiovasc. Interv.4, 266–272 (2011).
   PubMed Web of Science ®Google Scholar
• Sokos GG, Bolukoglu H, German J et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am. J. Cardiol.100, 824–829 (2007).
   PubMed Web of Science ®Google Scholar
• Müssig K, Oncü A, Lindauer P et al. Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with Type 2 diabetes. Am. J. Cardiol.102, 646–647 (2008).
   PubMedGoogle Scholar
• Lønborg J, Vejlstrup N, Kelbæk H et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur. Heart J. doi:10.1093/eurheartj/ehr309 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Poornima I, Brown SB, Bhashyam S, Parikh P, Bolukoglu H, Shannon RP. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ. Heart Fail.1, 153–160 (2008).
   PubMed Web of Science ®Google Scholar
• Vyas AK, Yang KC, Woo D et al. Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy. PLoS One6, e17178 (2011).
   Google Scholar
• Liu Q, Anderson C, Broyde A et al. Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc. Diabetol.9, 76 (2010).
   PubMed Web of Science ®Google Scholar
• Nikolaidis LA, Elahi D, Hentosz T et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation110, 955–961 (2004).
   PubMed Web of Science ®Google Scholar
• Nikolaidis LA, Elahi D, Shen YT, Shannon RP. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol.289, H2401–H2408 (2005).
   PubMed Web of Science ®Google Scholar
• Bhashyam S, Fields AV, Patterson B et al. Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy. Circ. Heart Fail.3, 512–521 (2010).
   PubMed Web of Science ®Google Scholar
• Gomez N, Touihri K, Matheeussen V et al. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur. J. Heart Fail.14, 14–21 (2012).
   PubMed Web of Science ®Google Scholar
• Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J. Card. Fail.12, 694–699 (2006).
   PubMed Web of Science ®Google Scholar
• Halbirk M, Nørrelund H, Møller N et al. Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am. J. Physiol. Heart Circ. Physiol.298, H1096–H1102 (2010).
   PubMedGoogle Scholar
• Nyström T, Gonon AT, Sjöholm A, Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul. Pept.125, 173–177 (2005).
   PubMed Web of Science ®Google Scholar
• Nathanson D, Erdogdu O, Pernow J, Zhang Q, Nyström T. Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo. Regul. Pept.157, 8–13 (2009).
   PubMed Web of Science ®Google Scholar
• Gaspari T, Liu H, Welungoda I et al. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model. Diab. Vasc. Dis. Res.8, 117–124 (2011).
   PubMed Web of Science ®Google Scholar
• Doran AC, Meller N, McNamara CA. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler. Thromb. Vasc. Biol.28, 812–819 (2008).
   PubMed Web of Science ®Google Scholar
• Vanhoutte PM. Endothelial dysfunction: the first step toward coronary arteriosclerosis. Circ. J.73, 595–601 (2009).
   PubMed Web of Science ®Google Scholar
• Arakawa M, Mita T, Azuma K et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes59, 1030–1037 (2010).
   PubMed Web of Science ®Google Scholar
• Goto H, Nomiyama T, Mita T et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochem. Biophys. Res. Commun.405, 79–84 (2011).
   PubMed Web of Science ®Google Scholar
• Murthy SN, Hilaire RC, Casey DB et al. The synthetic GLP-I receptor agonist, exenatide, reduces intimal hyperplasia in insulin resistant rats. Diab. Vasc. Dis. Res.7, 138–144 (2010).
   PubMedGoogle Scholar
• Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem. Biophys. Res. Commun.391, 1405–1408 (2010).
   PubMed Web of Science ®Google Scholar
• Liu H, Dear AE, Knudsen LB, Simpson RW. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J. Endocrinol.201, 59–66 (2009).
   PubMed Web of Science ®Google Scholar
• Hattori Y, Jojima T, Tomizawa A et al. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia53, 2256–2263 (2010).
   PubMed Web of Science ®Google Scholar
• Nagashima M, Watanabe T, Terasaki M et al. Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia54, 2649–2659 (2011).
   PubMed Web of Science ®Google Scholar
• Ta NN, Schuyler CA, Li Y, Lopes-Virella MF, Huang Y. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J. Cardiovasc. Pharmacol.58, 157–166 (2011).
   PubMed Web of Science ®Google Scholar
• Shah Z, Kampfrath T, Deiuliis JA et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation124, 2338–2349 (2011).
   PubMed Web of Science ®Google Scholar
• Basu A, Charkoudian N, Schrage W, Rizza RA, Basu R, Joyner MJ. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am. J. Physiol. Endocrinol. Metab.293, E1289–E1295 (2007).
   PubMed Web of Science ®Google Scholar
• Ceriello A, Esposito K, Testa R, Bonfigli AR, Marra M, Giugliano D. The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an ‘endothelial resistance’ to glucagon-like peptide 1 in diabetes. Diabetes Care34, 697–702 (2011).
   PubMed Web of Science ®Google Scholar
• Koska J, Schwartz EA, Mullin MP, Schwenke DC, Reaven PD. Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset Type 2 diabetes. Diabetes Care33, 1028–1030 (2010).
   PubMed Web of Science ®Google Scholar
• Lundkvist J, Berne C, Bolinder B, Jönsson L. The economic and quality of life impact of hypoglycemia. Eur. J. Health Econ.6, 197–202 (2005).
   PubMedGoogle Scholar
• Chico A, Vidal-Ríos P, Subirà M, Novials A. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with Type 1 and Type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care26, 1153–1157 (2003).
   PubMed Web of Science ®Google Scholar
• Cryer PE. Hypoglycemia: still the limiting factor in the glycemic management of diabetes. Endocr. Pract.14, 750–756 (2008).
   PubMedGoogle Scholar
• Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care33, 1389–1394 (2010).
   PubMed Web of Science ®Google Scholar
• Bonds DE, Miller ME, Bergenstal RM et al. The association between symptomatic, severe hypoglycaemia and mortality in Type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ340, b4909 (2010).
   PubMed Web of Science ®Google Scholar
• Yakubovich N, Gerstein HC. Serious cardiovascular outcomes in diabetes: the role of hypoglycemia. Circulation123, 342–348 (2011).
   PubMed Web of Science ®Google Scholar
• Johnston SS, Conner C, Aagren M, Smith DM, Bouchard J, Brett J. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with Type 2 diabetes. Diabetes Care34, 1164–1170 (2011).
   PubMed Web of Science ®Google Scholar
• Madsbad S, Krarup T, Deacon CF, Holst JJ. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr. Opin. Clin. Nutr. Metab. Care11, 491–499 (2008).
   PubMed Web of Science ®Google Scholar
• Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in Type 2 diabetes. JAMA303, 1410–1418 (2010).
   PubMed Web of Science ®Google Scholar
• Flynn C, Bakris GL. Blood pressure targets for patients with diabetes or kidney disease. Curr. Hypertens. Rep.13, 452–455 (2011).
   PubMed Web of Science ®Google Scholar
• Barragán JM, Rodríguez RE, Blázquez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7–36) amide in rats. Am. J. Physiol.266, E459–E466 (1994).
   Google Scholar
• Barragán JM, Rodríguez RE, Eng J, Blázquez E. Interactions of exendin-(9–39) with the effects of glucagon-like peptide-1-(7–36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Regul. Pept.67, 63–68 (1996).
   PubMed Web of Science ®Google Scholar
• Yu M, Moreno C, Hoagland KM et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J. Hypertens.21, 1125–1135 (2003).
   PubMed Web of Science ®Google Scholar
• Hirata K, Kume S, Araki S et al. Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochem. Biophys. Res. Commun.380, 44–49 (2009).
   PubMed Web of Science ®Google Scholar
• Horton ES, Silberman C, Davis KL, Berria R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with Type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care33, 1759–1765 (2010).
   PubMed Web of Science ®Google Scholar
• Mistry GC, Maes AL, Lasseter KC et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J. Clin. Pharmacol.48, 592–598 (2008).
   PubMed Web of Science ®Google Scholar
• Okerson T, Yan P, Stonehouse A, Brodows R. Effects of exenatide on systolic blood pressure in subjects with Type 2 diabetes. Am. J. Hypertens.23, 334–339 (2010).
   PubMed Web of Science ®Google Scholar
• Gill A, Hoogwerf BJ, Burger J et al. Effect of exenatide on heart rate and blood pressure in subjects with Type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc. Diabetol.9, 6 (2010).
   PubMed Web of Science ®Google Scholar
• Gallwitz B, Vaag A, Falahati A, Madsbad S. Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time. Int. J. Clin. Pract.64, 267–276 (2009).
   PubMedGoogle Scholar
• Pratley RE, Nauck M, Bailey T et al. Liraglutide versus sitagliptin for patients with Type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet375, 1447–1456 (2010).
   PubMed Web of Science ®Google Scholar
• Pinelli NR, Hurren KM. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. Ann. Pharmacother.45, 850–860 (2011).
   PubMed Web of Science ®Google Scholar
• Edwards CM, Edwards AV, Bloom SR. Cardiovascular and pancreatic endocrine responses to glucagon-like peptide-1(7–36) amide in the conscious calf. Exp. Physiol.82, 709–716 (1997).
   PubMedGoogle Scholar
• Buse JB, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for Type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet374, 39–47 (2009).
   PubMed Web of Science ®Google Scholar
• Blevins T, Pullman J, Malloy J et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab.96, 1301–1310 (2011).
   PubMed Web of Science ®Google Scholar
• Griffioen KJ, Wan R, Okun E et al. GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons. Cardiovasc. Res.89, 72–78 (2011).
   PubMedGoogle Scholar
• Gustavson SM, Chen D, Somayaji V et al. Effects of a long-acting GLP-1 mimetic (PF-04603629) on pulse rate and diastolic blood pressure in patients with Type 2 diabetes mellitus. Diabetes Obes. Metab.13, 1056–1058 (2011).
   PubMedGoogle Scholar
• Fox K, Borer JS, Camm AJ et al. Resting heart rate in cardiovascular disease. J. Am. Coll. Cardiol.50, 823–830 (2007).
   PubMed Web of Science ®Google Scholar
• Verdich C, Flint A, Gutzwiller JP et al. A meta-analysis of the effect of glucagon-like peptide-1 (7–36) amide on ad libitum energy intake in humans. J. Clin. Endocrinol. Metab.86, 4382–4389 (2001).
   PubMed Web of Science ®Google Scholar
• Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in Type 2 diabetes: a parallel-group study. Lancet359, 824–830 (2002).
   PubMed Web of Science ®Google Scholar
• Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology152, 3103–3112 (2011).
   PubMed Web of Science ®Google Scholar
• Orskov C, Poulsen SS, Møller M, Holst JJ. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes45, 832–935 (1996).
   PubMed Web of Science ®Google Scholar
• Harder H, Nielsen L, Tu DT, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care27, 1915–1921 (2004).
   PubMed Web of Science ®Google Scholar
• Jendle J, Nauck MA, Matthews DR et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for Type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes. Metab.11, 1163–1172 (2009).
   PubMed Web of Science ®Google Scholar
• Bunck MC, Diamant M, Eliasson B et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care33, 1734–1737 (2010).
   PubMed Web of Science ®Google Scholar
• Klonoff DC, Buse JB, Nielsen LL et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with Type 2 diabetes treated for at least 3 years. Curr. Med. Res. Opin.24, 275–286 (2008).
   PubMed Web of Science ®Google Scholar
• Edwards CM, Stanley SA, Davis R et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am. J. Physiol. Endocrinol. Metab.281, E155–E161 (2001).
   PubMed Web of Science ®Google Scholar
• Pinelli NR, Jantz A, Smith Z et al. Effect of administration time of exenatide on satiety responses, blood glucose, and adverse events in healthy volunteers. J. Clin. Pharmacol.51, 165–172 (2011).
   PubMed Web of Science ®Google Scholar
• Sze L, Purtell L, Jenkins A et al. Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader–Willi syndrome. J. Clin. Endocrinol. Metab.96, E1314–E1319 (2011).
   PubMed Web of Science ®Google Scholar
• Garber A, Henry R, Ratner R et al. Liraglutide versus glimepiride monotherapy for Type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, Phase III, double-blind, parallel-treatment trial. Lancet373, 473–481 (2009).
   PubMed Web of Science ®Google Scholar
• Holst JJ, Deacon CF, Vilsbøll T, Krarup T, Madsbad S. Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol. Med.14, 161–168 (2008).
   PubMed Web of Science ®Google Scholar
• Esposito K, Cozzolino D, Bellastella G et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in Type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes. Metab.13, 594–603 (2011).
   PubMed Web of Science ®Google Scholar
• Ansar S, Koska J, Reaven PD. Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins. Cardiovasc. Diabetol.10, 61 (2011).
   PubMed Web of Science ®Google Scholar
• Meier JJ, Gethmann A, Götze O et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia49, 452–458 (2006).
   PubMed Web of Science ®Google Scholar
• Matikainen N, Mänttäri S, Schweizer A et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with Type 2 diabetes. Diabetologia49, 2049–2057 (2006).
   PubMed Web of Science ®Google Scholar
• Schwartz EA, Koska J, Mullin MP, Syoufi I, Schwenke DC, Reaven PD. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset Type 2 diabetes mellitus. Atherosclerosis212, 217–222 (2010).
   PubMed Web of Science ®Google Scholar
• Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with Type 2 diabetes. Diabetes Obes. Metab.13, 366–373 (2011).
   PubMed Web of Science ®Google Scholar
• Hsieh J, Longuet C, Baker CL et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia53, 552–561 (2010).
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Salvadeo SA et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled Type 2 diabetes mellitus patients. Metabolism59, 887–895 (2010).
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Ferrari I et al. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled Type 2 diabetic patients. Horm. Metab. Res.42, 663–669 (2010).
   PubMed Web of Science ®Google Scholar
• Courrèges JP, Vilsbøll T, Zdravkovic M et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet. Med.25, 1129–1131 (2008).
   PubMed Web of Science ®Google Scholar
• Bethel MA, Green J, Califf RM, Holman RR. Rationale and design of the trial evaluating cardiovascular outcomes with sitagliptin (TECOS). Diabetes58(Suppl. 1), A555 (2009) (Abstract 2152-PO).
   Google Scholar
• White WB, Bakris GL, Bergenstal RM et al. Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE). A cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with Type 2 diabetes with acute coronary syndrome. Am. Heart J.162, 620–626.e1 (2011).
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E et al. The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus-Thrombolysis in Myocardial Infarction (SAVOR–TIMI) 53 Study. Am. Heart J.162(5), 818–825.e6 (2011).
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Marx N, Kahn SE et al. The rationale and design of the CAROLINA trial: an Active Comparator Cardiovascular Outcome Study of the DPP-4 Inhibitor Linagliptin in Patients with Type 2 Diabetes at High Cardiovascular Risk. Diabetes60(Suppl. 1), A303 (2011) (Abstract 1103-P).
   Google Scholar
• Williams-Herman D, Engel SS, Round E et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with Type 2 diabetes. BMC. Endocr. Disord.10, 7 (2010).
   PubMed Web of Science ®Google Scholar
• Schweizer A, Dejager S, Foley JE, Couturier A, Ligueros-Saylan M, Kothny W. Assessing the cardio–cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III Type 2 diabetes population. Diabetes Obes. Metab.12, 485–494 (2010).
   PubMed Web of Science ®Google Scholar
• White WB, Gorelick PB, Fleck P, Smith N, Wilson C, Pratley R. Cardiovascular events in patients receiving alogliptin: a pooled analysis of randomized clinical trials. Diabetes59(Suppl. 1), A105 (2010) (Abstract 391-PP).
   PubMedGoogle Scholar
• Frederich R, Alexander JH, Fiedorek FT et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for Type 2 diabetes. Postgrad. Med.122, 16–27 (2010).
   PubMed Web of Science ®Google Scholar
• Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with Type 2 diabetes. Cardiovasc. Diabetol.10, 22 (2011).
   PubMed Web of Science ®Google Scholar
• Marso SP, Lindsey JB, Stolker JM et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of Phase 2: 3 liraglutide clinical development studies. Diab. Vasc. Dis. Res.8, 237–240 (2011).
   PubMed Web of Science ®Google Scholar
• Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ. Cardiovascular safety with linagliptin in patients with Type 2 diabetes mellitus: a prespecified, prospective, and adjudicated meta-analysis of a Phase 3 programme. Cardiovasc. Diabetol.11, 3 (2012).
   PubMed Web of Science ®Google Scholar
• Monami M, Cremasco F, Lamanna C et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp. Diabetes Res.2011, 215764 (2011).
   PubMedGoogle Scholar
• Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr. Med. Res. Opin.27, 57–64 (2011).
   PubMed Web of Science ®Google Scholar
• Best JH, Hoogwerf BJ, Herman WH et al. Risk of cardiovascular disease events in patients withType 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care34, 90–95 (2011).
   PubMed Web of Science ®Google Scholar
• Best JH, Little W, Chiquette E, Saunders WB. The risk of heart failure among patients receiving exenatide versus other glucose-lowering medications for Type 2 diabetes: a matched retrospective cohort analysis of the GE healthcare electronic medical record database. Diabetes60(Suppl. 1), A311 (2011) (Abstract 1133-P).
   Google Scholar
• Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes. N. Engl. J. Med.353, 2643–5326 (2005).
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med.358, 2545–2559 (2008).
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with Type 2 diabetes. N. Engl. J. Med.358, 2560–2572 (2008).
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with Type 2 diabetes. N. Engl. J. Med.360, 129–139 (2009).
   PubMed Web of Science ®Google Scholar
• Treiman M, Elvekjaer M, Engstrøm T, Jensen JS. Glucagon-like peptide 1 – a cardiologic dimension. Trends Cardiovasc. Med.20, 8–12 (2010).
   PubMedGoogle Scholar
• Fadini GP, Boscaro E, Albiero M et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with Type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care33, 1607–1609 (2010).
   PubMed Web of Science ®Google Scholar
• Kanki S, Segers VF, Wu W et al. Stromal cell-derived factor-1 retention and cardioprotection for ischemic myocardium. Circ. Heart Fail.4, 509–518 (2011).
   PubMed Web of Science ®Google Scholar
• Scholte M, Timmers L, Bernink FJ et al. Effect of additional treatment with exenatide in patients with an acute myocardial infarction (EXAMI): study protocol for a randomized controlled trial. Trials12, 240 (2011).
   PubMedGoogle Scholar
• Hausenloy DJ, Yellon DM. Taking lizard saliva to heart. Eur. Heart J. doi:10.1093/eurheartj/ehr382 (2011) (Epub ahead of print).
   Google Scholar